


## Hemovigilance Module Adverse Reaction Transfusion Associated Graft vs. Host Disease

*Required for saving				
*Facility ID#:	NHSN Adverse Reaction #:	<u> </u>		
<b>Patient Informatio</b>	n			
*Patient ID:		*Date of Birth://		
*Sex: M F				
Social Security #:	Secondary ID:	Medicare #:		
Last Name:	First Name:	Middle Name:		
Ethnicity (Specify):	Hispanic or Latino Not Hispanic or Latino	Unknown Declined to respond		
Race (Select all that apply):	American Indian or Asian Alaska Native Native Hawaiian or White Pacific Islander	Black or African American African Unknown Declined to respond		
Preferred Language (\$	Specify from the list provided):	Interpreter Needed: Yes No Unknow Declined to Respond n		
*Blood Group: A-	A+ B- + AB- AB+  nsitional ABO / Rh + Transitional AB-  al Rh Group B/Transitional Rh Rh	Transitional ABO / Transitional		
Patient Medical Hi	story			
List the patient's ac	lmitting diagnosis. (Use ICD-10 Diagnostic	codes/descriptions)		
Code:	Description:			
Code:	Description:			
Code:				
	nderlying indication for transfusion. <i>(Use ICL</i>			
Code:				
Code:				
Code:	Description:			
	omorbid conditions at the time of the transfu -10 Diagnostic codes/descriptions)	sion related to the adverse UNKNOWN NONE		
Code:	Description:			
Code:				
Code:				

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). CDC 57.316 Rev. 3, v9.2

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666).







performed during the curre	nedical procedure including past procedures and procedures to be INKNOWN Int hospital or outpatient stay. (Use ICD-10 Procedure NONE
codes/descriptions)	
Code:	
Code:	
Code:	
Additional Information	
Transfusion History	
Has the patient received a	
Blood Product:	WB RBC Platelet Plasma Cryoprecipitate Granulocyte
Date of Transfusion:	// UNKNOWN
•	e reaction transfusion-related?YESNO
• •	about the transfusion adverse reaction.
	rse reaction: Allergic AHTR DHTR DSTR FNHTR
	PTP TACO TAD TA-GVHD TRALI UNKNOWN
	fy
Reaction Details	
	// *Time reaction occurred::: Time unknown
*Facility location where pati	
Is this reaction associated with	n an incident? Yes No If Yes, Incident #:
Investigation Results	graft va host disease (TA CVHD)
* Transfusion associated	graft vs. host disease (TA-GVHD)
	graft vs. host disease (TA-GVHD)
* Transfusion associated  *Case Definition	graft vs. host disease (TA-GVHD)  radiated blood product(s) in the two months preceding the reaction? Yes No
* Transfusion associated  *Case Definition  Did patient receive non-in	
* Transfusion associated  *Case Definition  Did patient receive non-in	radiated blood product(s) in the two months preceding the reaction? Yes No
* Transfusion associated  *Case Definition  Did patient receive non-in  Check all that occurred v  Clinical syndrome	radiated blood product(s) in the two months preceding the reaction? Yes No
* Transfusion associated  *Case Definition  Did patient receive non-ire  Check all that occurred v  Clinical syndrome  Clinical syndrome	radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion:
* Transfusion associated  *Case Definition Did patient receive non-ire  Check all that occurred value Clinical syndrome Clinical syndrome Liver dysfunc	radiated blood product(s) in the two months preceding the reaction? Yes No  vithin 2 days to 6 weeks after cessation of transfusion:  e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia
* Transfusion associated  *Case Definition Did patient receive non-iri  Check all that occurred v  Clinical syndrome Clinical syndrome Liver dysfunc  Characteristic	radiated blood product(s) in the two months preceding the reaction? Yes No  vithin 2 days to 6 weeks after cessation of transfusion:  e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia
* Transfusion associated  *Case Definition Did patient receive non-iri  Check all that occurred v  Clinical syndrome Clinical syndrome Liver dysfunc  Characteristic	radiated blood product(s) in the two months preceding the reaction? Yes No  vithin 2 days to 6 weeks after cessation of transfusion:  e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and
*Case Definition Did patient receive non-irr Check all that occurred war Clinical syndrome Clinical syndrome Liver dysfunction Characteristic may, in severe conceived war Clinical syndrome Check all that apply:	radiated blood product(s) in the two months preceding the reaction? Yes No  vithin 2 days to 6 weeks after cessation of transfusion:  e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and
*Case Definition Did patient receive non-irr Check all that occurred war Clinical syndrome Clinical syndrome Liver dysfunction Characteristic may, in severe conceived war Clinical syndrome Check all that apply:	radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion:  e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation.
*Case Definition Did patient receive non-iri Check all that occurred v Clinical syndrome Clinical syndrome Liver dysfunc Characteristic may, in severe co	radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion:  e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation.  ogical appearance of skin or liver biopsy.
*Case Definition Did patient receive non-iri Check all that occurred v Clinical syndrome Clinical syndrome Liver dysfunc Characteristic may, in severe control Characteristic histol Biopsy negative or i	radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion:  e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation.  ogical appearance of skin or liver biopsy.
*Case Definition Did patient receive non-irr Check all that occurred war Clinical syndrome Clinical syndrome Liver dysfunct Characteristic may, in severe control Check all that apply: Characteristic histol Biopsy negative or a Control Other signs and symptoms	radiated blood product(s) in the two months preceding the reaction? Yes No  vithin 2 days to 6 weeks after cessation of transfusion:  e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation.  ogical appearance of skin or liver biopsy.  not done.  : (check all that apply)
*Case Definition Did patient receive non-irr Check all that occurred v Clinical syndrome Clinical syndrome Liver dysfunc Characteristic may, in severe company in severe compa	radiated blood product(s) in the two months preceding the reaction?  Yes No  within 2 days to 6 weeks after cessation of transfusion:  e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation.  ogical appearance of skin or liver biopsy.  not done.  (check all that apply)  Chills/rigors Nausea/vomiting
* Transfusion associated  *Case Definition Did patient receive non-irr  Check all that occurred variable Clinical syndrome Clinical syndrome Clinical syndrome Liver dysfunce Characteristic may, in severe company, in severe company in severe compa	radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion:  e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia crash: erythematous, maculopapular eruption centrally that spreads to extremities and ases, progress to generalized erythroderma and hemorrhagic bullous formation.  ogical appearance of skin or liver biopsy.  not done.  : (check all that apply)



Hemolysis/Hemorrhage:	Disseminated intravascular coagulation Hemoglobinemia						
	Positive antibody screen						
Pain:	Abdominal pain	Back pain	Flank pain	Infusion site pain			
Renal:	Hematuria	Hemoglobinuria					
Respiratory:	Bronchospasm	Cough		Shortness of breath			
Other: (specify)	•						
*Severity							
Did the patient receive or	r experience any of the	following?					
No treatment requ	uired	Symptomatic tr	reatment only				
Hospitalization, in	Hospitalization, inlcuding prolonged hospitalization Life-threatening reaction						
Disability and/or in	• • • • •		omaly or birth defect(s	-			
	mportant conditions	Death	Unknown or no	•			
*Imputability	·						
*Imputability	ralationahin hatwaan tk	no transficcion and th	o roostion?				
Which best describes the No other alternativ	•	ie transiusion and th	ie reaction?				
	· ·	etam call transplanta	tion)				
	uses are present (e.g., s		•				
	ations are more likely (e		•	anat la a sualudad			
	in favor of a cause othe						
	e evidence beyond reaso						
•	etween the adverse reac		sion is unknown or no	t stated.			
Did the transfusion occur	at your facility?	YES NO					
WBC chimerism:	WBC chimerism prese	ent WBC	chimerism not presei	nt or not done			
<b>Module-generated Desig</b>							
NOTE: Designations for case application based on respons			, ,	d in the NHSN			
*Do you agree with the	case definition design	nation?	YES	NO			
^Please indicate your de							
*Do you agree with the	severity designation?	)	YES	NO			
^Please indicate your de	•						
*Do you agree with the		on?	YES	NO			
^Please indicate your de	signation						
Patient Treatment							
Did the patient receive trea	atment for the transfusio	n reaction?	YES NO	UNKNOWN			
If y <u>es,</u> select treatment(s)	):						
Medication (Select	the type of medication)						
Antipyretics	Antihistamines	Inotropes/Vasopre	ssors Bronchodil	lator Diuretics			
Intravenous							
Immunoglobulin		ravenous steroids	Corticosteroids	Antibiotics			
Antithymocyte	e globulin Cyclos	sporin Othe	er				



						3 - 1
Volu	ume resuscitation (Intr	avenous colloid	s or crystalloids)			
Res	piratory support <i>(Sele</i> Mechanical ventilati		<i>upport)</i> nvasive ventilation	Oxyger	١	
Ren	al replacement therap	oy <i>(Select the ty</i> Peritoneal	pe of therapy)  Continuous Ver	no-Venous Hem	ofiltration	
Phle Othe	ebotomy er Specify:					
Outcome						
		. —	ion to death:	Minor or no se		
Was an	autopsy performed?	Yes	No			
Component	Details					
*Was a partic	cular unit implicated	d in (i.e., respo	onsible for) the a	dverse	Yes No	N/A
Transfusion Start and End Date/Time	*Component code (check system used)	Amount transfused at reaction onset	^Unit number (Required for Infection and TRALI)	*Unit expiration Date/Time	*Blood group of unit	Implicat ed Unit?
Start and <b>End</b>	(check system used)	transfused at	(Required for Infection and	expiration		ed
Start and End Date/Time	(check system used)	transfused at	(Required for Infection and	expiration		ed
Start and End Date/Time	(check system used) UNIT USBT-128	transfused at reaction onset  Entire unit Partial unit	(Required for Infection and	expiration	of unit  A- A+ B-  B+ AB- AB+	ed Unit?
Start and End Date/Time	UNIT  ISBT-128  Codabar  ISBT-128  Codabar  Codabar	Entire unit Partial unit Entire unit Partial unit Partial unit Partial unit	(Required for Infection and	expiration	Of unit  A- A+ B-  B+ AB- AB+  O- O+ N/A  A- A+ B-  B+ AB- AB+	ed Unit?
Start and End Date/Time  ^IMPLICATED //://://	UNIT  ISBT-128  Codabar  ISBT-128  Codabar  Codabar	Entire unit Partial unit Entire unit Partial unit Partial unit Partial unit	(Required for Infection and	expiration	Of unit  A- A+ B-  B+ AB- AB+  O- O+ N/A  A- A+ B-  B+ AB- AB+	ed Unit?
Start and End Date/Time  ^IMPLICATED //://:// Custom Field	UNIT  ISBT-128  Codabar  ISBT-128  Codabar  Codabar	Entire unit Partial unit Entire unit Partial unit Partial unit Partial unit	(Required for Infection and TRALI)	expiration	Of unit  A- A+ B-  B+ AB- AB+  O- O+ N/A  A- A+ B-  B+ AB- AB+	ed Unit?



Form Approved OMB No. 0920-0666 Exp. Date: 12/31/0207

www.cdc.gov/nhsn